Elysium Health Launches At-Home Test to Measure Rate of Aging, Biological Age
Elysium Heath also announced Morgan Levine, Ph.D., of Yale School of Medicine has joined the company as head of bioinformatics to improve the testing methodology of Index, with the goal of making its application accurate and informative for individuals.
Mayo Clinic Names Head of New Digital Healthcare Platform
John Halamka, M.D., will oversee Mayo Clinic Platform as it carries out initial projects focused on home healthcare scheduling, patient data uploading, and supplying patient-specific treatment information based on Mayo Clinic data.
Promega to Develop MSI Technology as CDx to Merck’s Keytruda
Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
8 Companion Diagnostic Developers Making a Mark
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
Qiagen, DiaSorin Launch Automated Workflow for QFT-Plus in U.S. Following FDA Approval
QFT-Plus is designed to offer streamlined laboratory automation for latent TB screening, supporting conversion from century-old tuberculin skin tests to fourth-generation blood-based QuantiFERON technology.
![Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). [Source: Eraxion/Getty]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1893-218x150.jpeg "Pre-Surgical Immunotherapy for Lung Cancer Shows Positive Results")
Pre-Surgical Immunotherapy for Lung Cancer Shows Positive Results
Researchers from the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and nine other centers, presented interim results at the American Society of Clinical Oncology...
Artificial Intelligence Enhances Oncology
The volume of information that needs to be analyzed to make precision medicine a reality in cancer care is often beyond the realm of the human mind. That’s where artificial intelligence steps in
![ArcherDX said its Archer Immunoverse and VariantPlex NGS assays will be used by Ambry toward offering its biopharma customers large-scale immune repertoire analysis and chimeric antigen T-cell receptor (CAR-T) manufacturing characterization and pharmacodynamics. [royaltystockphoto/Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1550-218x150.jpeg "Metabolic Imbalance Associated with Resistance to Checkpoint Inhibitor Nivolumab")
Metabolic Imbalance Associated with Resistance to Checkpoint Inhibitor Nivolumab
Investigators at the Dana-Farber Cancer Institute, in conjunction with researchers at the Broad Institute of MIT and Harvard, have discovered that a metabolic imbalance...
Duke Researchers Show How Stem Cell Mutations Arise and Metastasize in the Colon
The researchers used a Cancer rainbow (Crainbow) modeling system for fluorescently barcoding somatic mutations to directly visualize the clonal expansion and spread of oncogenes.
Veracyte Nabs Exclusive Global License for Diagnostic Use of Nanostring’s nCounter Technology
The company will initially use the FDA-cleared, automated nCounter system which can simultaneously analyze RNA, DNA or protein targets in up to 800 genes, for uses in diopathic pulmonary fibrosis diagnosis and breast cancer diagnosis.
